$2.15 Billion is the total value of Cormorant Asset Management, LP's 73 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
SPY | New | SPDR S&P 500 ETF TRput | $257,750,000 | – | 1,000,000 | +100.0% | 11.98% | – |
XLRN | New | ACCELERON PHARMA INC | $74,143,000 | – | 825,000 | +100.0% | 3.44% | – |
RVMD | New | REVOLUTION MEDICINES INC | $60,627,000 | – | 2,767,078 | +100.0% | 2.82% | – |
AGEN | New | AGENUS INC | $29,827,000 | – | 12,174,486 | +100.0% | 1.39% | – |
BEAM | New | BEAM THERAPEUTICS INC | $14,336,000 | – | 796,429 | +100.0% | 0.67% | – |
FIXX | New | HOMOLOGY MEDICINES INC | $9,324,000 | – | 600,000 | +100.0% | 0.43% | – |
INSM | New | INSMED INC | $5,807,000 | – | 362,273 | +100.0% | 0.27% | – |
ARCT | New | ARCTURUS THERAPEUTICS HLDG I | $3,561,000 | – | 262,037 | +100.0% | 0.16% | – |
FATE | New | FATE THERAPEUTICS INC | $1,666,000 | – | 75,000 | +100.0% | 0.08% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
OMEROS CORP | 27 | Q3 2021 | 6.5% |
MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2024-05-08 |
SC 13G | 2024-04-29 |
4 | 2024-04-22 |
SC 13G/A | 2024-04-15 |
4 | 2024-04-03 |
SC 13G | 2024-03-21 |
4 | 2024-03-18 |
SC 13G/A | 2024-03-18 |
4 | 2024-03-11 |
13F-HR | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.